What this is
- How it works
- How it works isn't classified yet
- Tested for
- Follicular Lymphoma (FL), Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL), Transformed Follicular Lymphoma (TFL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Main trialPhase 2
- “This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a). The primary endpoint is objective response rate (ORR) assessed by independent review using the Lugano 2014 classification.”In the company’s words, NCT07360288 on ClinicalTrials.gov
Other drugs for Follicular Lymphoma (FL)
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TazemetostatEpizyme, Inc. · Phase 3
- EpcoritamabGenmab · Phase 3
- OdronextamabRegeneron · Phase 3
- SurovatamigAstraZeneca · Phase 3
- GolcadomideCelgene · Phase 3
Coming up2
- 11 Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 31 May 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 May 2028 | Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma | |
| Phase 1/2Recruiting | 11 Feb 2028 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026